SCHEMBL21165030

SCHEMBL21165030

Cc1cc(C(O)CN2CCCC2)c(C)n1-c1cccc(Cl)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.48
IGF1R P08069 1/20 0.46
ALDH1A1 P00352 3/20 0.45
MAPT P10636 3/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
USP14 P54578 1/20 0.44
USP7 Q93009 1/20 0.44
TP53 P04637 1/20 0.43
RECQL P46063 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
CYP2C19 P33261 1/20 0.42
HIF1A Q16665 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19501173 0.81 SMN1; SMN2 (0.53) NOTUMALDH1A1HPGDSMN1; SMN2USP14
SCHEMBL6921452 0.79 USP14 (0.56) NOTUMIGF1RALDH1A1HPGDSMN1; SMN2
SCHEMBL21165029 0.76 HPGD (0.45) IGF1RALDH1A1MAPTGAAHPGD
SCHEMBL6922487 0.75 SMN1; SMN2 (0.78) NOTUMALDH1A1MAPTHPGDSMN1; SMN2
SCHEMBL19749177 0.72 GAA (0.46) NOTUMIGF1RALDH1A1MAPTGAA
SCHEMBL21165185 0.71 KDM4E (0.40) HPGDSMN1; SMN2USP14USP7HTR7
SCHEMBL23559540 0.69 SMN1; SMN2 (0.49) NOTUMIGF1RALDH1A1HPGDSMN1; SMN2
SCHEMBL23559501 0.68 SMN1; SMN2 (0.48) NOTUMIGF1RALDH1A1HPGDSMN1; SMN2
SCHEMBL5736618 0.67 L3MBTL1 (0.49) GAASMN1; SMN2MEN1KMT2AALOX15
SCHEMBL8944148 0.66 IGF1R (0.79) IGF1RMAPTRECQLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10351568-B2 Compositions and methods for enhancing proteasome activity PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2019-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10351568-B2 Compositions and methods for enhancing proteasome activity PSMG3, PSME3, PSMB11 NOTUM 2331/4885IGF1R 4166/4885ALDH1A1 4165/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.